Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2020
Event: Entry into a Material Definitive Agreement and Unregistered Sale of Equity Securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Preferred Private Placement: Issuance of 438,885 shares of Series A Convertible Preferred Stock to RA Capital Healthcare Fund, L.P. at $455.70 per share.
- Total Gross Proceeds (Preferred): Approximately $200.0 million.
- Common Private Placement: Sale of 32,916 shares of Common Stock to David M. Mott at $45.57 per share.
- Total Gross Proceeds (Common): Approximately $1.5 million.
- Effective Common Price: $45.57 per share (based on a 1:10 conversion ratio for Preferred Stock).
- Closing Date: June 16, 2020.
Material Changes and Terms
The filing reports the creation of a new class of equity and specific rights associated with the Series A Convertible Preferred Stock:
- Conversion Rights: Each Preferred share converts into 10 Common shares. Conversion is subject to a 9.99% beneficial ownership blocker.
- Mandatory Conversion: Required upon the earlier of the tenth anniversary of issuance or immediately prior to a change of control transaction.
- Redemption Rights: The Investor may redeem shares at the purchase price if the Company fails to file required registration statements, maintain effectiveness of such statements for one year, or file financial statements regarding the acquisition of Praha Vaccines a.s.
- Liquidation Preference: In a liquidation event (excluding change of control), holders receive the greater of the purchase price plus unpaid dividends or the value if converted to Common Stock immediately prior to liquidation.
- Voting Rights: Preferred Stock does not vote on matters submitted to Common Stock holders but holds veto rights over amendments affecting its specific rights.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) regarding the capital raise but does not contain forward-looking guidance on revenue or product timelines within the text provided.
Risks and Contingencies:
- Registration Risk: The Investor has redemption rights triggered if the Company fails to file a Form S-3 or prospectus supplement by August 19, 2020, or fails to maintain its effectiveness.
- Transfer Restrictions: Preferred Stock may not be transferred without the Company's prior written consent.
- Dilution: The transaction results in the issuance of new equity, subject to the 9.99% blocker provision.
Investor Verification Checklist
- Verify the effectiveness of the resale registration statement (Form S-3) required to be filed by August 19, 2020.
- Confirm the status of the financial statements related to the acquisition of Praha Vaccines a.s., as failure to file these triggers redemption rights.
- Review the full Subscription Agreement (Exhibit 10.1) for detailed covenants and conditions not summarized in the 8-K.
- Monitor the 9.99% beneficial ownership blocker to understand potential limitations on the Investor's ability to convert shares.